Erlanger Cardiology completed the first in Chattanooga concomitant left atrial appendage closure (LAAC) and cardiac ablation ...

In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant ...

It's the season for parties and celebrating the end of another year, but having a few too many drinks can leave you feeling less than merry.Perhaps it's a thumping headache, a feeling of "jitteriness" ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today ...

Athletes who undergo ablation to treat their irregular heartbeat caused by atrial fibrillation (AF) experience greater ...

AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration ...

CardioFocus has treated the first patients in an investigational trial of OptiShot, its pulsed field ablation (PFA) system ...

In patients with atrial fibrillation, a resting heart rate of 80 bpm or higher is associated with increased risk for mortality.

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated ...

CardioFocus announced that investigators completed the first series of treatments in a study of its OptiShot pulsed-field ...